, Volume 58, Issue 2, pp 289–294 | Cite as

The radiographically diagnosed adrenal myelolipoma: what do we really know?

  • Michael J. Campbell
  • Mary Obasi
  • Bingling Wu
  • Michael T. Corwin
  • Ghaneh Fananapazir
Original Article



Adrenal myelolipomas are uncommon, benign tumors of the adrenal glands that are not routinely evaluated for autonomous hormone secretion or followed by repeat imaging, but may lead to retroperitoneal hemorrhage. Little is known about the natural history these tumors with the majority of previous publications being confined to case reports and small case series.


We reviewed the computed tomography (CT) reports of 62,279 patients evaluated at a tertiary referral center between 2002 and 2015 for the presence of an adrenal myelolipoma >1 cm in size. We then reviewed the CT imaging and patient charts to determine tumor size, growth, evidence of retroperitoneal hemorrhage, and endocrine dysfunction.


We identified 150 (0.24%) patients with 155 radiographically diagnosed adrenal myelolipomas found on a CT scan during our study period. The median tumor size at discovery was 2.1 cm. Twelve (7.7%) tumors were >6 cm. Sixty-nine (46%) patients had a follow-up CT with a mean time interval between scans of 3.9 years. Eleven tumors (16%) grew over our follow-up period with a median growth rate of 0.16 cm/year. No patient developed a retroperitoneal hemorrhage. Twenty (13%) patients underwent an evaluation for endocrine dysfunction. Three patients had evidence of hypercortisolism and one patient had primary aldosteronism.


The majority of radiographically diagnosed adrenal myelolipomas found on abdominal CT imaging are small and slow growing. Retroperitoneal hemorrhage is uncommon, but the rate of associated endocrine dysfunction may be underestimated.


Adrenal myelolipoma Adrenal incidentaloma Hypercortisolism 



Department funds were used for incidental expenses. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The requirement for informed consent was waived for this study by our institutional review board.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    J. Dinnes, I. Bancos, L. Ferrante di Ruffano et al., Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur. J. Endocrinol. 175(2), R51–R64 (2016).CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    M. Fassnacht, W. Arlt, I. Bancos et al., Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 175(2), G1–G34 (2016).CrossRefPubMedGoogle Scholar
  3. 3.
    M.A. Zeiger, G.B. Thompson, Q.Y. Duh et al., American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations. Endocr. Pract. 15(5), 450–453 (2009).CrossRefPubMedGoogle Scholar
  4. 4.
    L.L. Berland, S.G. Silverman, R.M. Gore et al., Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J. Am. Coll. Radiol. 7(10), 754–773 (2010).CrossRefPubMedGoogle Scholar
  5. 5.
    A. Plaut, Myelolipoma in the adrenal cortex; myeloadipose structures. Am. J. Pathol. 34(3), 487–515 (1958).PubMedPubMedCentralGoogle Scholar
  6. 6.
    K.Y. Lam, C.Y. Lo, Adrenal lipomatous tumors: a 30 year clinicopathological experience at a single institution. J. Clin. Pathol. 54(9), 707–712 (2001).CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    J.H. Song, F.S. Chaudhry, W.W. Mayo-Smith, The incidental adrenal mass on CT: prevalence of adrenal disease in 1049 consecutive adrenal masses in patients with no known malignancy. Am. J. Roentgenol. 190(5), 1163–1168 (2008).CrossRefGoogle Scholar
  8. 8.
    E.M. Schaeffer, L.R. Kavoussi, Adrenal myelolipoma. J. Urol. 173(5), 1760 (2005).CrossRefPubMedGoogle Scholar
  9. 9.
    V.G. Patel, O.A. Babalola, J.K. Fortson et al., Adrenal myelolipoma: report of a case and review of the literature. Am. Surg. 72(7), 649–654 (2006).PubMedGoogle Scholar
  10. 10.
    H.C. Su, X. Huang, W.L. Zhou et al., Pathologic analysis, diagnosis and treatment of adrenal myelolipoma. Can. Urol. Assoc. J. 8(9-10), E637–E640 (2014).CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    S. Daneshmand, M. Quek, Adrenal myelolipoma: diagnosis and management. Urol. J. 3(2), 71–74 (2006).PubMedGoogle Scholar
  12. 12.
    J. Vierna, J.B. Laforga, Giant adrenal myelolipoma. Report of a case and review of the literature. Scand. J. Urol. Nephrol. 28, 301–304 (1994).PubMedGoogle Scholar
  13. 13.
    V.G. Shenoy, A. Thota, R. Shankar et al., Adrenal myelolipoma: controversies in its management. Indian J Urol. 31(2), 94–101 (2015).CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    M. Nishino, J.P. Jagannathan, N.H. Ramaiya et al., Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am. J. Roentgenol. 195(2), 281–289 (2010).CrossRefGoogle Scholar
  15. 15.
    D. Mozaffarian, E.J. Benjamin, A.S. Go et al., Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133(4), e38–e360 (2016).CrossRefPubMedGoogle Scholar
  16. 16.
    M. Han, A.L. Burnett, E.K. Fishman et al., The natural history and treatment of adrenal myelolipoma. J. Urol. 157(4), 1213–1216 (1997).CrossRefPubMedGoogle Scholar
  17. 17.
    M. Peppa, E. Boutati, C. Koliaki et al., Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause–effect relationship. Metabolism 59(10), 1435–1441 (2010).CrossRefPubMedGoogle Scholar
  18. 18.
    V.S. Katabathina, E. Flaherty, R. Kaza et al., Adrenal collision tumors and their mimics: multimodality imaging findings. Cancer Imaging 13(4), 602–610 (2013).CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    P.J. Kennedy, B.J. Wagner, P. Rao et al., Myelolipoma: CT and pathologic features. Radiology 208(1), 87–95 (1998).CrossRefGoogle Scholar
  20. 20.
    P. Otal, G. Escourrou, C. Mazerolles et al., Imaging features of uncommon adrenal masses with histopathologic correlation. Radiographics 19(3), 569–581 (1999).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Michael J. Campbell
    • 1
  • Mary Obasi
    • 1
  • Bingling Wu
    • 1
  • Michael T. Corwin
    • 1
  • Ghaneh Fananapazir
    • 1
  1. 1.Departments of Surgery and RadiologyUniversity of California, Davis Medical CenterSacramentoUSA

Personalised recommendations